FDG PET: advantages for staging the mediastinum?

Lung Cancer. 2004 Aug:45 Suppl 2:S69-74. doi: 10.1016/j.lungcan.2004.07.990.

Abstract

Correctly staging lung cancer is extremely important because treatment options and prognosis differ significantly by stage. In this review, the performance characteristics of positron emission tomography using F-18-fluoro-deoxyglucose (FDG PET) for staging the mediastinum are given in comparison with other non-invasive imaging modalities on the basis of current literature data. There are three meta-analyses demonstrating that FDG PET is more accurate than CT for detecting mediastinal metastases. First publications suggest that dual-modality PET-CT may provide a further gain in accuracy. Additionally, whole-body FDG PET provides information on M-staging and prognosis. Data comparing FDG PET with other functional imaging modalities or endoscopic ultrasound are limited. The necessity of a histological confirmation of PET results is still under discussion.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / diagnostic imaging*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Cost Savings
  • Endosonography
  • Fluorodeoxyglucose F18*
  • Humans
  • Lung Neoplasms / diagnostic imaging*
  • Lung Neoplasms / pathology
  • Magnetic Resonance Imaging
  • Mediastinum / diagnostic imaging*
  • Mediastinum / pathology
  • Neoplasm Staging / methods*
  • Prognosis
  • Radiopharmaceuticals*
  • Tomography, Emission-Computed / methods*
  • Tomography, X-Ray Computed

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18